A study evaluated the pharmacokinetics of a novel commercial formulation of ivermectin in goats. Six healthy adult goats received 200 µg/kg of ivermectin via intravenous (IV) and subcutaneous (SC) routes. Plasma samples were collected over 36 and 42 days, respectively. Drug concentrations were measured using high-performance liquid chromatography with fluorescence detection. After IV administration, ivermectin followed a 2-compartment open model, with a volume of distribution at steady state of 9.94 L/kg, clearance of 1.54 L/kg/d, and AUC of 143 (ng·d)/mL. Noncompartmental analysis showed a mean residence time of 7.37 days, AUC of 153 (ng·d)/mL, and clearance of 1.43 L/kg/d. After SC administration, noncompartmental analysis revealed a maximum plasma concentration (Cmax) of 21.8 ng/mL, time to reach Cmax of 3 days, and bioavailability (F) of 91.8%. The study found that the novel formulation had high bioavailability and higher Cmax and time to reach Cmax compared to other studies. Ivermectin is a semisynthetic derivative of avermectin B1, used as an antiparasitic in livestock, pets, and humans. Its pharmacokinetics vary based on administration route, formulation, and species. The study highlights the importance of understanding pharmacokinetics for optimizing drug efficacy in goats. The novel formulation showed good absorption and higher exposure compared to other routes. The study also noted that pharmacokinetic differences between species can affect drug efficacy. The results suggest that the novel formulation is a good option for ivermectin administration in goats due to its high bioavailability and effective plasma concentrations. The study provides valuable pharmacokinetic data for the use of ivermectin in goats, which is essential for its rational use.A study evaluated the pharmacokinetics of a novel commercial formulation of ivermectin in goats. Six healthy adult goats received 200 µg/kg of ivermectin via intravenous (IV) and subcutaneous (SC) routes. Plasma samples were collected over 36 and 42 days, respectively. Drug concentrations were measured using high-performance liquid chromatography with fluorescence detection. After IV administration, ivermectin followed a 2-compartment open model, with a volume of distribution at steady state of 9.94 L/kg, clearance of 1.54 L/kg/d, and AUC of 143 (ng·d)/mL. Noncompartmental analysis showed a mean residence time of 7.37 days, AUC of 153 (ng·d)/mL, and clearance of 1.43 L/kg/d. After SC administration, noncompartmental analysis revealed a maximum plasma concentration (Cmax) of 21.8 ng/mL, time to reach Cmax of 3 days, and bioavailability (F) of 91.8%. The study found that the novel formulation had high bioavailability and higher Cmax and time to reach Cmax compared to other studies. Ivermectin is a semisynthetic derivative of avermectin B1, used as an antiparasitic in livestock, pets, and humans. Its pharmacokinetics vary based on administration route, formulation, and species. The study highlights the importance of understanding pharmacokinetics for optimizing drug efficacy in goats. The novel formulation showed good absorption and higher exposure compared to other routes. The study also noted that pharmacokinetic differences between species can affect drug efficacy. The results suggest that the novel formulation is a good option for ivermectin administration in goats due to its high bioavailability and effective plasma concentrations. The study provides valuable pharmacokinetic data for the use of ivermectin in goats, which is essential for its rational use.